MedPath

ELITE LABORATORIES, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 3:2

Drug Approvals

9

FDA:9

Drug Approvals

Trimipramine Maleate

Approval Date
Dec 29, 2019
FDA

Isradipine

Approval Date
Dec 27, 2019
FDA

Dantrolene Sodium

Approval Date
Dec 27, 2019
FDA

Acetaminophen and Codeine Phosphate

Approval Date
Sep 10, 2019
FDA

Loxapine

Approval Date
Apr 18, 2019
FDA

PHENDIMETRAZINE TARTRATE

Approval Date
Feb 7, 2019
FDA

Phentermine Hydrochloride

Approval Date
Apr 14, 2017
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (100.0%)

A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery

Phase 3
Completed
Conditions
Pain
Interventions
First Posted Date
2015-03-30
Last Posted Date
2016-08-09
Lead Sponsor
Elite Laboratories, Inc
Target Recruit Count
163
Registration Number
NCT02401750
Locations
🇺🇸

Premier Research, Austin, Texas, United States

🇺🇸

Chesapeake Research Group, Pasadena, Maryland, United States

🇺🇸

Endeavor Clinial Trials, San Antonio, Texas, United States

and more 1 locations

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

Phase 3
Completed
Conditions
Withdrawal Symptoms
Interventions
Drug: Oxycodone/Naltrexone Capsules
Drug: Placebo
First Posted Date
2015-03-18
Last Posted Date
2016-08-10
Lead Sponsor
Elite Laboratories, Inc
Target Recruit Count
26
Registration Number
NCT02391571
Locations
🇺🇸

Vince and Associates, Overland Park, Kansas, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath